Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22121365 | 1.00 | ACHE (0.50) | ACHEHRH4HRH3EPHX1NPC1 | |
| SCHEMBL30010462 | 0.83 | ACHE (0.50) | ACHEHRH4HRH3EPHX1 | |
| SCHEMBL31113456 | 0.83 | ACHE (0.50) | ACHEHRH4HRH3EPHX1 | |
| SCHEMBL4921718 | 0.83 | ACHE (0.53) | ACHEEPHX1 | |
| SCHEMBL12393903 | 0.82 | HRH4 (0.50) | ACHEHRH4HRH3 | |
| SCHEMBL345235 | 0.79 | ACHE (0.56) | ACHEEPHX1 | |
| SCHEMBL15775056 | 0.78 | ACHE (0.60) | ACHEEPHX1 | |
| SCHEMBL1486852 | 0.77 | ACHE (0.55) | ACHEEPHX1 | |
| SCHEMBL855002 | 0.75 | ACHE (0.67) | ACHEEPHX1 | |
| SCHEMBL11146652 | 0.74 | ACHE (0.50) | ACHEHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673445-A1 | STING AGONISTS CONTAINING BENZYLIC ALCOHOL AND BENZYLIC AMINE FUNCTIONAL GROUPS | BioNTech SE (DE) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024180103-A1 | STING AGONISTS CONTAINING BENZYLIC ALCOHOL AND BENZYLIC AMINE FUNCTIONAL GROUPS | BioNTech SE (DE) | 2024-09-06 | — | — | WO | disclosed |
| US-20220267364-A1 | HETEROCYCLIC AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2022-08-25 | — | — | US | disclosed |
| WO-2020132582-A1 | STING AGONISTS AND USES THEREOF | NIMBUS TITAN, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267364-A1 | HETEROCYCLIC AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | STING1, CGAS, VIP | ACHE 1432/4885HRH4 67/4885HRH3 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.